Technology/ Title

High yield CHO production system

Technology Type

Biotechnology

□Device/Diagnostics

Pharmaceutical

□Others:_____________-

Contact Person

Name: Pang-Hsi Liu

Title: Project Manager

Telephone(work): +886-02-7700-3830 ext. 37

Email: albertliu@dcb.org.tw

2019 BioAsia

Information

Download

https://www.dcb.org.tw/posts/729

 

 

Technology Description

 

  • Field/Type : Cell Engineering/platform  
  • Introduction:

CHO-C, a high yield CHO production system, including the optimized expression vector, IP protected host cell, suspension-adapted CHO cell lines and well established process and feeding strategy, has been developed and already entered into the  commercial stage:

  1. Current feed batch culture has a maximum output of 4.7 g/L. The toolbox includes new high-yield expression vectors, next-generation target integration technology, adaptation of host cells, optimization of culture conditions and feeding strategies.
  2. Compared with the commercially available vector, the antibody yield is about 1.3-2 times and the optimization for different CHO cells are continued. Our next generation target integration technology increase the cell productivity per copy to about 3-5 times higher than that of traditional means. By optimizing the basal medium and feeding strategies, fed-batch culture can further increase the batch production by 7-15 times.
  3. The engineered CHO host cells has been established into the cGMP-grade cell bank, which has a better survival rate and may maintain stably for 100 generations.

All toolboxes and technologies keep being developed and optimized.

  • Application:

Biologics product production

Intellectual Property

US provisional patent, PCT and TW patents applied

Business Opportunity

Biologics product production

 

▌技術簡介(現況)

  1. 高產量CHO細胞表現系統包含自有載體、自有CHO細胞宿主、及製程開發,提供蛋白藥物開發廠商有別於市面上的CHO表現系統技術之非專屬授權,在抗體的產量及質量皆有競爭力。加上量身打造的製程開發,配合委託服務可提供一整套的技術移轉。
  2. 可提供委託服務: 從載體設計,細胞株開發,高產量位點定點嵌入皆可提供客製化服務。

 

▌技術規格

高產量CHO細胞表現平台 (包括自有載體、自有CHO細胞宿主、及製程開發)。

 

▌技術特色

本技術自有宿主CHO-C細胞株為CHO-DXB11改良後的新型細胞株,可利用此平台簡易篩選及製程放大建立高產量抗體細胞株此系統特色:

  1. 具有GMP等級的CHO-C細胞株
  2. 包含自有開發載體及特殊訊息胜肽
  3. 自有開發高產量嵌入位點
  4. 從Flask->250mL->5L生物反應器穩定製程放大
  5. 高產量及高穩定度 (3~5 g/L; 100代穩定度)
  6. 簡易授權模式 (不需royalties/milestone fee)

 

▌應用範圍

可應用生產IgG, scFV等不同format抗體蛋白或是重組蛋白。

 

▌接受技術者具備基礎建議(設備)

細胞培養設備; 無菌操作; flask等級或是5L生物反應器

 

▌接受技術者具備基礎建議(專業)

具備抗體生產所需能力

 

▌技術分類

生技醫藥

 

▌專利狀態

已申請美國臨、PCT、台灣專利。


聯絡人:劉邦熙 專案經理

TEL(02) 2652-2677 # 37

E-mailalbertliu@dcb.org.tw

最後更新日期:2019.03.27